docCompany Presentation
download 
Report Transcription
Company Presentation
Siegfried at a Glance June 2015 Who are we? — Company founded 140 years ago — Long-term tradition of pharmaceutics and chemicals — Unique selling proposition (USP): Development and manufacturing services of chemical and pharmaceutical industry — Production of active pharmaceutical ingredients (API), intermediates and Drug Products — Total number of employees: Approx. 2200 (FTE as of December 31, 2015) — World-class integrated service partner regarding Quality and Compliance — Listed on the Swiss Stock Exchange SIX Siegfried at a Glance — Financially independent and robust 2 Why Siegfried? — Bringing together our more than 140 years Pharma and Chemical heritage, we offer as an integrated partner benefit to our customers with more synergy, expertise and value — Integrated supply of APIs and finished products — Toughened stance by FDA: Siegfried for several years inspected with «no action indicated» Siegfried at a Glance 3 Siegfried’s Growth Builds on Three Distinct Businesses Tailor-Made for Four Target Business Segments Underlying business models: — Contract development and manufacturing — In-house development — Co-development Siegfried at a Glance 4 Our Vision Siegfried is a world-class integrated service partner to the global pharmaceutical industry in the development and manufacture of drug substances and drug products that improve life. Siegfried at a Glance 5 A Multinational Company with Manufacturing Assets in Europe, North America and Asia Siegfried at a Glance 6 History Siegfried at a Glance 7 History 1873 Pharmacist Samuel Benoni Siegfried founds a company with 12 employees as a supplier to pharmacies 1904 Conversion into a joint stock corporation 1928 Founding of Ganes Chemical Works, Inc. (NJ, USA) 1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 Focus on development and custom manufacturing Siegfried at a Glance 8 History 2001 – Building of two core divisions: Siegfried and Sidroga – Integration of Ganes into the Siegfried Group = Siegfried (USA) Inc. 2005 Acquisition of Penick Corporation in New Jersey, USA 2007 – Launch of a new pharmaceutical production facility in Malta – Sale of the Sidroga Division – Sale of the biotech activities 2008 Sale of the pharmaceutical production site Zofingen Siegfried at a Glance 9 History 2010 Definition of new strategy «Transform» 2012 Acquisition of Alliance Medical Products (AMP) in Irvine, CA, USA 2013 Construction of new production site Nantong/China and Zofingen 2014 Acquisition of Hameln Pharma in Hameln (DE) 2015 Acquisition of BASF sites in Minden (DE), Evionnaz (CH) and St. Vulbas (FR) Siegfried at a Glance 10 Management Siegfried at a Glance 11 Organizational chart Siegfried Group Siegfried Holding Chairman A. Casutt Siegfried Group R. Hanko 1 (CEO) Ass. A.M. Laudano Pool Office / Travel Office A. Laudano Corporate Communications P. Gehler Global Planning and Portfolio Management K. Stingl Corporate Counsel Compliance P. Kiechle Global Head Business Development M. Späne 1 Siegfried at a Glance Operations W. Kittl 1 IT, Business Excellence & Procurement Ch. Neubaur 2 Research & Development R. Imwinkelried 1 Strategy, M&A, Legal and Regulatory Affairs W. Wienand 1 1 Member Executive Committee 2 Reporting line IT Finance M. Hüsler 1 Human Resources A. Middel 1 12 Management Board of Directors Andreas Casutt Chairman Martin Schmid Colin Bond Ulla Schmidt Wolfram Carius Thomas Villiger Reto Garzetti Siegfried at a Glance 13 Management Executive Committee Dr. Rudolf Hanko Chief Executive Officer Marianne Späne Head Business Development, Marketing & Sales Michael Hüsler Chief Financial Officer Dr. Walter Kittl Head Technical Operations Arnoud M. Middel Head Human Resources Dr. René Imwinkelried Head Research & Development Dr. Wolfgang Wienand Head Strategy and Mergers & Acquisitions Siegfried at a Glance 14 Human Resources Siegfried at a Glance 15 Human Resources Vision — Socially responsible employer — Personal responsibility — Motivated and talented personnel — Focusing on results — Mutual respect — Open and transparent communication — Entrepreneurial thinking and acting — Performance-oriented company culture Siegfried at a Glance 16 Human Resource Development Employees per December 31, 2015 Location Number of FTE Zofingen 485 Pennsville 178 Malta 123 Irvine 87 Nantong 163 Hameln 416 Evionnaz 321 Minden 333 St. Vulbas 132 Total 2238 Siegfried at a Glance 17 Financials Siegfried at a Glance 18 Net sales 2015 2014 Change CHF (LC) Drug Substances 333.2 234.4 +42.1% (+43.4%) Drug Products 147.4 80.9 +82.4% (+100%) Total 480.6 315.3 +52.4% (+57.9%) CHF million Siegfried at a Glance 19 Sales Drug Substances and Drug Products Total sales 2015 broken down into Drug Substances and Drug Products 69.3% Drug Substances 30.7% Drug Products Siegfried at a Glance 20 Business Development Net sales 500 480.6 450 400 374.9 350 367.8 300 250 314.4 289.3 315.3 328.1 283.0 200 2008 2009 Siegfried at a Glance 2010 2011 2012 2013 2014 2015 21 Business Development Share price development from January 1, 2011 to December 31, 2015 Siegfried at a Glance 22 Strategy Siegfried at a Glance 24 Milestones of the «Transform» strategy Siegfried at a Glance 25 The Transform strategy has been completed with the recent acquisition of three BASF sites Defensive strategy − − − − Asset management, consolidation Focus on improved cost position Top-line effect mainly as result of improved costs Exploitation of synergies between API / solid drug products Forward-oriented strategy − − − − Acquisition of new technologies for API manufacture Acquisition sterile manufacturing Top-line effect as result of acquisition plus best ownership Synergies between API / sterile drug products Siegfried at a Glance Backward integration to Asia Achieve critical size Construction of a production facility in Zofingen (Deliver) Fwd integration (sterile filling) Special technologies 26 Thank You! Siegfried at a Glance 27
